Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease
Fujimaki M, Saiki S, Li Y, Kaga N, Taka H, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Koinuma T, Ueno SI, Imamichi Y, Ueno T, Miura Y, Funayama M, Hattori N
Neurology · 69 citas
Etiquetas de revisión
Vínculos de autores con la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de casos y controles (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Japan Society for the Promotion of Science
- Autores
- Al menos un autor declara un vínculo económico con la industria
- Subvenciones
- Japan Society for the Promotion of Science (15KK0354); Japan Society for the Promotion of Science (18K07829); Japan Society for the Promotion of Science (16K09675); Japan Society for the Promotion of Science (17K07797); Japan Society for the Promotion of Science (15H04843); Japan Society for the Promotion of Science (16K09676); Japan Society for the Promotion of Science (16K01834)
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2018-01-04 · Neurology · vol. 90 · número 5 · págs. e404–e411
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 103 citas · más que el 98% de estudios similares · 8.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 40 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Coffee research and impacts · Parkinson's Disease Mechanisms and Treatments · Adenosine and Purinergic Signaling
- Palabras clave
- Caffeine, Metabolite, CYP1A2, Paraxanthine, Adenosine receptor, Biomarker, Parkinson's disease, Internal medicine, Area under the curve, Chemistry, Metabolomics, Pharmacology, Endocrinology, Medicine, Receptor, Cytochrome P450, Metabolism, Biochemistry, Disease, Chromatography
- MeSH
- humans, parkinson disease, 3-iodobenzylguanidine, caffeine, cytochrome p-450 cyp1a2, cytochrome p-450 cyp2e1, chromatography, liquid, severity of illness index, case-control studies, retrospective studies, mutation, aged, middle aged, female, male, mass spectrometry, myocardial perfusion imaging, biomarkers
17 autores
- Motoki Fujimaki
- Shinji Saiki
- Yuanzhe Li
- Naoko Kaga
- Hikari Taka
- Taku Hatano
- Kei‐ichi Ishikawa
- Yutaka Oji
- Akio Mori
- Ayami Okuzumi
- Takahiro Koinuma
- Shin‐Ichi Ueno
- Yoko Imamichi
- Takashi Ueno
- Yoshiki Miura
- Manabu Funayama
- Nobutaka Hattori
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
To investigate the kinetics and metabolism of caffeine in serum from patients with Parkinson disease (PD) and controls using liquid chromatography-mass spectrometry.
Methods
Levels of caffeine and its 11 metabolites in serum from 108 patients with PD and 31 age-matched healthy controls were examined by liquid chromatography-mass spectrometry. Mutations in caffeine-associated genes were screened by direct sequencing.
Results
Serum levels of caffeine and 9 of its downstream metabolites were significantly decreased even in patients with early PD, unrelated to total caffeine intake or disease severity. No significant genetic variations in CYP1A2 or CYP2E1, encoding cytochrome P450 enzymes primarily involved in metabolizing caffeine in humans, were detected compared with controls. Likewise, caffeine concentrations in patients with PD with motor complications were significantly decreased compared with those without motor complications. No associations between disease severity and single nucleotide variants of the ADORA2A gene encoding adenosine 2A receptor were detected, implying a dissociation of receptor sensitivity changes and phenotype. The profile of serum caffeine and metabolite levels was identified as a potential diagnostic biomarker by receiver operating characteristic curve analysis.
Conclusion
Absolute lower levels of caffeine and caffeine metabolite profiles are promising diagnostic biomarkers for early PD. This is consistent with the neuroprotective effect of caffeine previously revealed by epidemiologic and experimental studies.
Classification of evidence
This study provides Class III evidence that decreased serum levels of caffeine and its metabolites identify patients with PD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.